HKSH Mobile App | Wechat Booking
Request an Appointment | Online Booking
What's New
Submitted by CADLanceCheung on 2026-07-07
2026-07-07
HKSH’s First-in-Asia Comparative Study on Radiotherapy for Breast Cancer Reveals Hypofractionated Proton Therapy Prevents Breast Cancer Recurrence with 100% Survival Rate Minimises Cardiopulmonary Concerns and Maintains Quality of Life
(7 July 2026, Hong Kong) The HKSH Cancer Centre under HKSH Medical Group (HKSH) introduced proton therapy in 2023, covering a wide range of cancer types including breast, prostate as well as head and neck cancers, and has since accumulated about 940 cases of clinical data. Around 45% of its proton therapy treatments involve breast cancer patients receiving postoperative radiotherapy to reduce the risk of recurrence. Leveraging its clinical experience and innovative technologies in breast cancer proton therapy, HKSH has presented two clinical studies focusing on Chinese breast cancer patients at the Asia-Oceania Particle Therapy Co-operative Group 2025 (PTCOG-AO) and Particle Therapy Co-operative Group Annual Conference 2026 (PTCOG). Both studies are the first of their kind in Asia and further advance precision medicine aimed at helping patients “live with cancer while preserving quality of life.”
Please click here for more details.
Please click here for more details.
FRAUD ALERT: Reports have been received from the public about fraudulent calls impersonating Hong Kong Sanatorium & Hospital, falsely claiming uncollected medical documents. Do not respond or share personal information. Please be aware of bogus communications (fraudulent websites, emails and phone calls) purportedly from HKSH Medical Group or its members including Hong Kong Sanatorium & Hospital, HKSH Healthcare, HKSH Eastern Medical Centre, HKSH Cancer Centre and affiliates. Do not disclose any personal information to suspicious calls. Please call HKSH Medical Group at 2572 0211 if you have any concerns.
